COPD exacerbations are reduced by budesonide/formoterol in a single inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003
Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol in a single inhaler improves asthma control more effectively than a higher dose of fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Cardiovascular effects of a high dose of the budesonide/formoterol single inhaler in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 54s Year: 2001
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002
Budesonide/formoterol in a single inhaler rapidly improves lung function in adult patients with mild or moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
The effect of inhaler switching on asthma and COPD patients Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018
Comparison of inhaler and nebuliser bronchodilator treatments in COPD attacks Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002
Beclometasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002
Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients Source: International Congress 2016 – Asthma management Year: 2016
Early and sustained benefits of budesonide and formoterol in a single inhaler vs fluticasone in moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Preference for novel soft mist inhaler over pMDI in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008